Patient Burden Associated with Pneumococcal Disease

Author(s):

Christina M. Madison, PharmD, FCCP, AAHIVP,Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP

A medical professional examines the significant patient burden imposed by pneumococcal infections, highlighting how this burden drove the development of innovative vaccine technologies.

EP: 1.Symptomatology and Transmission of Pneumococcal Infection

EP: 2.Manifestation of Pneumococcal Disease in Adults

EP: 3.High-Risk Populations for Severe Pneumococcal Infection

Now Viewing

EP: 4.Patient Burden Associated with Pneumococcal Disease

EP: 5.Vaccination Efforts to Mitigate Pneumococcal Outbreaks

EP: 6.Comparing and Contrasting the Characteristics of the FDA-Approved Pneumococcal Vaccines

EP: 7.Target Patient Populations for Pneumococcal Vaccines

EP: 8.ACIP Recommendations for Pneumococcal Vaccination

EP: 9.Clinical Considerations for Pneumococcal Vaccination Scheduling

EP: 10.Clinical Data Supporting Pneumococcal Vaccination

EP: 11.Insights on Conjugate Pneumococcal Vaccines

EP: 12.Future Considerations for Pneumococcal Vaccination

EP: 13.Barriers to Administering Pneumococcal Vaccines and Best Practices for Overcoming Them

EP: 14.Optimizing Pneumococcal Vaccination Efforts in High-Risk Patients

EP: 15.Closing Thoughts From The Panel On Pneumococcal Vaccination

Discuss the patient burden of pneumococcal infections that led to the development of novel vaccines.